AEON Biopharma, Inc. Class A (AEON)

Over the past six months, AEON Biopharma's stock has been influenced by several events. Positive biosimilarity results for ABP-450 were reported in November 2025. Constructive FDA feedback was received in January 2026. A $6 million PIPE financing and debt reduction were announced in March 2026. Full-year 2025 financial results were reported on March 30, 2026, showing a net loss and $3.0 million in cash. NYSE American listing standards notices were received in late March and early April 2026. John Bencich was appointed as CFO in March 2026. The stock price increased by 109.64% year-over-year as of April 8, 2026, but decreased by -12.38% in the past month and -17.04% over the past six months.

Information on demand seasonality for AEON Biopharma's products is not readily available. As a clinical-stage company, revenue generation is minimal, and demand for ABP-450 is contingent on regulatory approval and commercialization. While therapeutic botulinum toxins may have some seasonality depending on the treated conditions, this is not directly addressed for AEON's specific product in its current development stage.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing botulinum toxins for medical conditions, particularly in the neurosciences market. Their main product, ABP-450 (prabotulinumtoxinA) injection, is being developed as a biosimilar to BOTOX® for therapeutic uses, pursuing regulatory approval through the U.S. biosimilar pathway. ABP-450 has completed a Phase 2 study for cervical dystonia and has an ongoing Phase 2 study for chronic and episodic migraine. It is also being developed for gastroparesis and post-traumatic stress disorder and is manufactured by Daewoong Pharmaceutical in a cGMP-compliant facility.

AEON Biopharma, Inc. is headquartered in Irvine, California, United States. The company possesses exclusive rights to develop and distribute ABP-450 for therapeutic purposes in key regions, including the United States, Canada, the European Union, the United Kingdom, and other international territories.

AEON Biopharma's brand reputation is influenced by the progress of ABP-450 as a BOTOX® biosimilar and its financial stability. Positive developments include comparative analytical results for ABP-450 and favorable FDA feedback. Strategic financing and debt reduction efforts also contribute positively. Challenges include reliance on ABP-450's success, concerns about FDA strictness with biosimilar toxins, and NYSE American listing standard notices.

AEON Biopharma's ownership includes institutional, insider, and retail investors. Institutional investors own approximately 8.65% to 22.78% of the stock, with major holders including Dauntless Investment Group, LLC, and Vanguard Group Inc. Retail investors hold about 50.54% of the stock. Insiders own approximately 39.96%, with CEO Robert E. Bancroft holding the most shares. Daewoong Co., Ltd. holds a significant portion, approximately 47.46% of the shares.